Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Neoplasms

Gland and Hormone Related Diseases

Rare Diseases

Renal Insufficiency

Kidney Failure, Chronic

Neoplasm Metastasis

Hyperparathyroidism

Hyperparathyroidism, Secondary

Neoplastic Processes

Kidney Diseases

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Parathyroid Diseases

Endocrine System Diseases

Renal Insufficiency, Chronic

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Bone Density Conservation Agents

Micronutrients

All Drugs and Chemicals

Vasoconstrictor Agents

Vitamins

Vitamin D

Cholecalciferol

Calcitriol

Hormones

Calcium

Calcium, Dietary

Trace Elements

Vitamin D3

Calciferol

DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks

Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks

DP001 softgel capsules

Placebo

Ravi Thadhani, MD

The goal of this study is to test a new vitamin D compound for its ability to reduce parathyroid hormone levels in patients who are on hemodialysis.

This is a randomized, double-blind, placebo-controlled study of the vitamin D analog 2-methylene-19-nor-20S-1α,25-dihydroxyvitamin D3 (DP001) in patients with end-stage renal disease (ESRD). The effect of 12 weeks of oral administration of DP001 on serum parathyroid hormone (PTH) levels will be evaluated in ESRD patients who have secondary hyperparathyroidism.

A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

Deltanoid Pharmaceuticals

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis	NCT01922843	Hyperparathyroi... Kidney Failure,...	DP001 softgel c... Placebo	18 Years -	Deltanoid Pharmaceuticals
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis	NCT01922843	Hyperparathyroi... Kidney Failure,...	DP001 softgel c... Placebo	18 Years -	Deltanoid Pharmaceuticals

Spots Global Cancer Trial Database for dp001 softgel capsules